Combating COVID-19: Best Practices That Clinicians Need to Know
How should clinicians combat coronavirus disease (COVID-19) in their practice settings?
How should clinicians combat coronavirus disease (COVID-19) in their practice settings?
Ubrogepant, the newly approved calcitonin gene-related peptide antagonist, can relieve migraine symptoms within 2 hours after initial dose.
A study investigated the factors that add to unnecessary lumbar spine MRIs in uncomplicated low-back pain.
Patients perception of poor sleep differ from EEG-reported results.
Blood biomarkers currently do not have diagnostic value for patients with suspected TIA, indicating that the sudden onset of symptoms and “onset in full intensity” are still the most valuable clinical predictors of TIA and minor stroke.
Investigators aimed to determine the prevalence of concentrate use and associated risk factors among adolescents who used cannabis.
Investigators assessed whether glial fibrillary acidic protein and ubiquitin C-terminal hydrolase may be effective biomarkers for detecting concussive, subconcussive, and nonconcussive injuries in pediatric and adult patients with normal mental status following trauma.
Giant cell arteritis has been vastly studied in white populations; however, its significance among other racial and ethnic groups is not as well known.
The association between disease activity and emotional processing biases may play a role in the higher rates of depression in patients with inflammatory bowel disease.
Investigators studied the effects of midlife high or increasing blood pressure on late-life brain structure.